A total of 153 samples (swabs) were taken from burned patients between the ages of 2 and 75, representing a variety of age groups and body regions. All samples were obtained from Baghdad’s government hospitals. Beginning in early September 2022 and ending in early January 2023, (48/153) isolates (31.37%) were identified as P. aeruginosa Testing for antibiotic susceptibility It was conducted using various antibiotic classes (8 antibiotics), which were assessed using the VITEK 2 compact system. The results revealed that P. aeruginosa isolates were resistant to ceftazidime and cefepime (100%) in the same rate, the resistance to Tobramycin and Ciprofloxacin was (77.08), and the maximum sensitivity to Colistin was )79.1) and resistance to imipenem, meropenem, and Levofloxacin was (52.08%), (79.18%), and (72.92%), respectively. In this study used zirconium nanoparticles for inhibition growth bacteria. The efficacy of the synthetic nanoparticles against P. aeruginosa was tested as five different concentrations (1,2.5,5,10 and 15) mg/ml were adopted, and concentrations of (5,10 and 15) mg/ml showed efficacy in inhibiting bacterial growth while (1 and 2.5) mg/ml was not given any effectiveness, the results of minimum inhibitory concentration was (5) mg\ml.